Conference Coverage

Risk Stratification May Mitigate Adverse Events Associated With Newer MS Drugs

Neurology Reviews. 2013 December;21(12):18

 

References

—Erik Greb
Senior Associate Editor

Pages

Recommended Reading

Which Factors Predict Whether a Patient With MS Will Switch Therapies?
MDedge Neurology
Tobias Derfuss, MD, Part 2
MDedge Neurology
Tobias Derfuss, MD, Part 1
MDedge Neurology
FDA panel has mixed votes on alemtuzumab for multiple sclerosis
MDedge Neurology
Fine-Tuning the Ketogenic Diet May Benefit Children With Epilepsy—And Other News From the Child Neurology Society Meeting
MDedge Neurology
What Is the Future of Disease-Modifying Therapies for MS?
MDedge Neurology
New and Noteworthy Information—December 2013
MDedge Neurology
Teriflunomide Is Safe and Effective for Patients With CIS—Main Results From the TOPIC Study
MDedge Neurology
Repetitive TMS May Reduce Depression and Fatigue in Patients With MS
MDedge Neurology
Conference News Update—Society for Neuroscience
MDedge Neurology